NMD4C Reaches 800 Member Milestone
We are thrilled to announce that the NMD4C has reached the milestone of 800 members! This incredible number shows the strength and engagement of the diverse neuromuscular community in Canada.
Each member plays a vital role in uniting the NMD4C’s efforts toward our shared goal of improving the research, treatment, and care of neuromuscular diseases for all Canadians. We are deeply grateful for your ongoing support and participation, and the NMD4C’s success has only been possible because of your commitment and contributions and we look forward to continuing this important work together!
Read next...
Hope on the Horizon: Trials, Treatments and Therapies for DMD, DM1 & MG
Nov 25-28, 2025 | Join us at Hope on the Horizon to learn more about the treatment and clinical trial landscape for Duchenne Muscular Dystrophy, Myotonic Dystrophy Type 1 and Myasthenia Gravis from key experts in the field!
2026 Awards Now Open for Nominations!
We’re proud to recognize outstanding achievements across the neuromuscular research community with our Three awards: Publication of the Year, Early Career Biomedical/Clinical Researchers of the Year.
A Milestone in Neuromuscular Care: AGAMREE® (vamorolone) Approved as the First Treatment for Duchenne Muscular Dystrophy in Canada
Health Canada has approved AGAMREE® (vamorolone), the first-ever treatment for Duchenne Muscular Dystrophy (DMD) in Canada. Patient Support Program opens for enrollment on October 10, 2025.